Clene, Inc. (CLNN)
4.16
+0.06
(+1.34%)
USD |
NASDAQ |
Sep 02, 16:00
4.19
+0.03
(+0.72%)
After-Hours: 20:00
Clene Research and Development Expense (Annual) : 12.66M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 12.66M |
| December 31, 2024 | 18.68M |
| December 31, 2023 | 25.22M |
| December 31, 2022 | 31.13M |
| Date | Value |
|---|---|
| December 31, 2021 | 27.62M |
| December 31, 2020 | 14.30M |
| December 31, 2019 | 8.763M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 3.976M |
| Summit Therapeutics, Inc. | 537.67M |
| Kezar Life Sciences, Inc. | 33.76M |
| Protara Therapeutics, Inc. | 42.49M |